Experimental CAR-T therapy takes on Hard-to-Treat lupus nephritis
NCT ID NCT06342960
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial is testing a personalized cell therapy called KYV-101 for people with lupus nephritis that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. Only 2 participants are enrolled, and the main goal is to check safety and how the therapy affects the immune system.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KYV-101 CAR-T cell therapy (a personalized immune cell treatment) plus standard chemotherapy drugs (cyclophosphamide and fludarabine) to prepare the body
What this could lead to
If successful, this could point toward a new way to control severe lupus nephritis by resetting the immune system, potentially reducing the need for lifelong medications.
What could go wrong
This is a very early, tiny trial with only 2 participants, so results may not apply to others. CAR-T therapy carries risks like severe immune reactions and infections, and it is not yet known if it can safely control lupus long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charite- Universitätsklinikum Berlin
Berlin, Germany
-
Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP
Frankfurt, Germany
-
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, Germany
-
Universitätsklinikum Düsseldorf
Düsseldorf, Germany
-
Universitätsklinikum Erlangen
Erlangen, Germany
-
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany